الفهرس 
Introduction and Aim of workOnly 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
Diabetes is a metabolic disorder which is characterized by hyperglycemia and glucose intolerance due to insulin deficiency, impaired effectiveness of insulin action or, both. Type I diabetes mellitus (Type I DM) is caused by cellular-mediated autoimmune destruction of pancreatic islet beta-cells leading to loss of insulin production. It usually starts during childhood, but can occur at all ages. Type II DM accounts for 90%–95% of all diabetes and is more common in people older than 45 who are overweight.
Ischemic heart disease is the leading cause of death in the industrialized world. The treatment of acute ischemic heart disease has entered a new era in which mortality can be approximately halved by procedures that allow the rapid return of blood flow to the ischemic zone of the myocardium, i.e., reperfusion therapy.
Resveratrol as a natural antioxidant, it can halt free radical damage and open abnormally narrowed arterial passageways, Pretreatment with resveratrol is effective to prevent reperfusion induced injury. The protective effects by resveratrol may be associated with its antioxidant activity, free radicals scavenging activity and enhanced NO release during the reperfusion period
Rosiglitazone is a member of the thiazolidinedione class of drugs,the mechanism of action of rosiglitazone is through activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect.
Rosuvastatin is approved for the treatment of high LDL cholesterol , hypercholesterolemia, and/or hypertriglyceridemia . In February 2010, rosuvastatin was approved by the FDA for the primary prevention of cardiovascular events.
The present work aimed mainly to:
1- Clarify the adverse effects of diabetes during myocardial ischemia reperfusion.
2- Evaluate the cardioprotective effect of resveratrol (natural antioxidant) either as monotherapy or in combination with rosiglitazone in modulating cardiovascular complications in diabetes during myocardial ischemia reperfusion.
3- Elucidate whether rosiglitazone (PPAR-γ agonist) may offer additional benefits over rosuvastatin in attenuating the development of cardiovascular complications associated with diabetes during ischemia-reperfusion.
To fulfill such objectives, the following parameters were selected to be studied:
In serum: glucose, lipid profile, Creatine kinase –MB, TNF-α.
In cardiac tissue: INOS, Mmp-9, NF-kβ, PPAR-γ, VEGF, GSH, MDA.